An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

NCT04538989 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Congenital Hyperinsulinism

Interventions

DRUG: RZ358 Sequential Group Cohort 1
DRUG: RZ358 Sequential Group Cohort 2
DRUG: RZ358 Sequential Group Cohort 3
DRUG: RZ358 Sequential Group Cohort 4

Sponsor

Rezolute